- Company unveils new innovative Oncology organization, strategic
vision and approach, following the Seagen acquisition in late
2023
- Robust portfolio and R&D engine with 8+ potential
blockbuster medicines by 2030
- Multiple near- and mid-term catalysts expected to help drive
long-term sustainable growth
At a meeting with the investment community today, Pfizer Inc.
(NYSE: PFE) outlined its strategic priorities for the newly formed
Oncology organization — and how its deep and diverse pipeline,
industry-leading Oncology expertise, and anticipated near- and
mid-term catalysts are expected to position the company to deliver
strong growth and shareholder value. A replay of the webcast and
related materials, including the presentations and a summary and
transcript, will be made available on the Pfizer investor relations
website at www.pfizer.com/investors.
“With the completion of the Seagen acquisition in 2023, Pfizer
has significantly expanded its Oncology organization to amplify its
efforts to advance new standards of care and improve outcomes for
patients,” said Chris Boshoff, Chief Oncology Officer and Executive
Vice President, Pfizer. “With the energy of our highly talented
colleagues, the tremendous potential of our pipeline and scientific
engine, and scale of the Pfizer enterprise, we believe we are
poised to deliver on our vision of accelerating breakthroughs that
help people with cancer globally live better and longer lives.”
Boshoff continued, “We have a clear strategy focused on three
core scientific modalities and four main types of cancer, where we
have the deep expertise and knowledge to advance our leadership.
With many significant catalysts expected through the first half of
2025 and beyond, our Oncology organization is well-positioned to be
a critical driver of potential long-term sustainable sales and
profit growth for Pfizer through the end of the decade.”
During the event, Chris Boshoff and members of the Pfizer
Oncology leadership team highlighted the company’s expanded
capabilities and portfolio following the completion of the
acquisition of Seagen in December 2023. Pfizer Oncology is focused
on expanding its leadership in four main cancer types: breast
cancer, including three main hormonal subtypes; genitourinary
cancer, including prostate and urothelial cancers;
hematology-oncology, including multiple myeloma and lymphomas, such
as Hodgkin’s disease; and thoracic cancers, which includes lung and
head and neck cancers.
Pfizer’s Oncology portfolio is focused on three core scientific
modalities: small molecules, antibody drug conjugates (ADCs), and
bispecific antibodies, including other immuno-oncology biologics.
The company is progressing a next-generation ADC platform aimed at
novel targets and improved, differentiated payloads, as well as
investigational advanced biologics and novel combinations of
medicines.
The company outlined potential significant catalysts anticipated
through the first half of 2025, including:
- Continued focus on four recent priority indication launches,
including PADCEV® (enfortumab vedotin-ejfv) in combination with
pembrolizumab in locally advanced / metastatic urothelial cancer;
XTANDI® (enzalutamide) in nonmetastatic castration-sensitive
prostate cancer (nmCSPC) with biochemical recurrence at high-risk
for metastasis; TALZENNA® (talazoparib) in combination with XTANDI
in metastatic castration-resistant prostate cancer (mCRPC); and
ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients
with relapsed or refractory multiple myeloma who have received at
least four prior lines of therapy.
- Seven anticipated Phase 3 readouts, including results for
vepdegestrant in second-line estrogen receptor positive metastatic
breast cancer (ER+ mBC) (VERITAC-2), BRAFTOVI® (encorafenib) in
first-line BRAF+ metastatic colorectal cancer (BREAKWATER),
sasanlimab in non-muscle invasive bladder cancer (CREST), and
ELREXFIO in double-class exposed relapsed/refractory multiple
myeloma (MagnetisMM-5).
- Six anticipated Phase 3 study starts, which includes three new
trials recently initiated for key pipeline assets: atirmociclib
(CDK4i) in second-line hormone receptor positive (HR+) mBC,
sigvotatug vedotin (B6A; integrin beta-6 (IB6)-directed ADC) in
second/third-line non-small cell lung cancer (NSCLC), and ELREXFIO
in patients with multiple myeloma after their cancer progresses on
anti-CD38 treatment (MagnetisMM-32 trial).
- Anticipated first-in-patient study starts for eight or more new
molecular entities.
During the meeting, Pfizer also shared new or updated clinical
data from various pipeline programs, including atirmociclib,
ELREXFIO, felmetatug vedotin (B7H4 ADC), mevrometostat (EZH2i),
PD-L1 ADC (PF-08046054), and sigvatutag vedotin.
Through its strategy, by 2030, the company anticipates 8 or more
potential blockbusters and expects biologics to contribute
approximately 65% of Oncology revenues, compared to approximately
6% in 2023.
Prescribing Information for Pfizer Medicines
Please see full Prescribing Information for PADCEV® (enfortumab
vedotin).
Please see full Prescribing Information for TALZENNA®
(talazoparib).
Please see full Prescribing Information for XTANDI®
(enzalutamide).
Please read full Prescribing Information, including BOXED
WARNING, for ELREXFIOTM (elranatamab-bcmm).
Please see full Prescribing Information for BRAFTOVI®
(encorafenib).
About Pfizer Oncology
At Pfizer Oncology, we are at the forefront of a new era in
cancer care. Our industry-leading portfolio and extensive pipeline
includes game-changing mechanisms of action to attack cancer from
multiple angles, including antibody-drug conjugates (ADCs), small
molecules, bispecific antibodies and other immunotherapy biologics.
We are focused on delivering transformative therapies in some of
the world’s most common cancers, including breast cancer,
genitourinary cancer, hematology-oncology, and thoracic cancers,
which includes lung cancer. Driven by science, we are committed to
accelerating breakthroughs that help people with cancer globally
live better and longer lives.
About Pfizer: Breakthroughs That Change Patients’
Lives
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety, and value
in the discovery, development, and manufacture of health care
products, including innovative medicines and vaccines. Every day,
Pfizer colleagues work across developed and emerging markets to
advance wellness, prevention, treatments, and cures that challenge
the most feared diseases of our time. Consistent with our
responsibility as one of the world's premier innovative
biopharmaceutical companies, we collaborate with health care
providers, governments, and local communities to support and expand
access to reliable, affordable health care around the world. For
more than 175 years, we have worked to make a difference for all
who rely on us. We routinely post information that may be important
to investors on our website at www.pfizer.com. In addition, to
learn more, please visit us on www.pfizer.com and follow us on X at
@Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook
at Facebook.com/Pfizer.
Disclosure Notice
The information contained in this release is as of February 29,
2024. The Company assumes no obligation to update forward-looking
statements contained in this release as the result of new
information or future events or developments.
This release contains forward-looking statements about Pfizer
Oncology; our anticipated operating and financial performance,
including financial guidance and projections; changes to Pfizer’s
commercial organization; reorganizations; business plans, strategy,
goals and prospects, including our 2030 goals; expectations for our
product pipeline, in-line products and product candidates,
including anticipated regulatory submissions, data read-outs, study
starts, approvals, launches, clinical trial results and other
developing data, revenue contribution and projections, potential
pricing and reimbursement, potential market dynamics, size and
utilization rates, growth, performance, timing of exclusivity and
potential benefits; plans for and prospects of our recent
acquisition of Seagen and our ability to successfully capitalize on
this opportunity; manufacturing and product supply; and other
statements about our business, operations and financial results
that are subject to substantial risk and uncertainties. Among other
things, statements regarding revenue; anticipated operating and
financial performance; the development or commercial potential of
our product pipeline, in-line products, product candidates and
additional indications or combinations, including expected clinical
trial protocols, the potential and timing for the initiation and
progress of clinical trials and data read-outs from trials; the
timing and potential for the submission of applications for and
receipt of regulatory approvals; the timing and potential for
product launches and commercialization; expected profile and
labeling; potential revenue; expected breakthrough, best- or
first-in-class or blockbuster status or expected market entry of
our medicines; potential patients reached; potential portfolio
composition; the regulatory landscape; and the competitive
landscape are forward-looking and are estimates that are subject to
change and subject to, among other risks, assumptions and
uncertainties, the uncertainties inherent in research and
development, including the ability to meet anticipated clinical
endpoints, commencement and/or completion dates for our clinical
trials, regulatory submission dates, regulatory approval dates
and/or launch dates, as well as the possibility of unfavorable new
clinical data and further analyses of existing clinical data; risks
associated with interim and preliminary data; the risk that
clinical trial data are subject to differing interpretations and
assessments by regulatory authorities; whether regulatory
authorities will be satisfied with the design of and results from
our clinical studies; whether and when any drug applications,
biologics license applications and/or emergency use authorization
applications may be filed in any jurisdictions for any potential
indication for Pfizer’s product candidates; whether and when any
such applications that may be filed for any of Pfizer’s product
candidates may be approved by regulatory authorities, which will
depend on myriad factors, including making a determination as to
whether the product's benefits outweigh its known risks and
determination of the product's efficacy and, if approved, whether
any such product candidates will be commercially successful;
decisions by regulatory authorities impacting labeling,
manufacturing processes, safety and/or other matters that could
affect the availability or commercial potential of Pfizer’s product
candidates, including development of products or therapies by other
companies; manufacturing capabilities or capacity; uncertainties
regarding the ability to obtain recommendations from vaccine
technical committees and other public health authorities and
uncertainties regarding the commercial impact of any such
recommendations; uncertainties regarding the commercial success of
Pfizer’s products and product candidates; uncertainties regarding
the impact of COVID-19 on Pfizer’s business, operations and
financial results; and competitive developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2023 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229001671/en/
Media Contact: +1 (212) 733-1226
PfizerMediaRelations@Pfizer.com
Investor Contact: +1 (212) 733-4848 IR@Pfizer.com
Pfizer (NYSE:PFE)
過去 株価チャート
から 3 2024 まで 4 2024
Pfizer (NYSE:PFE)
過去 株価チャート
から 4 2023 まで 4 2024
